ArticleScience advances2025

Safety and immunogenicity of intranasal parainfluenza virus type 5 (PIV5)-vectored COVID-19 vaccine in adults and teens in an open-label phase 1 trial.

Paul Spearman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.